Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

NCT02263326 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

89

Enrollment

OTHER

Sponsor class

Conditions

HIV Infection

Interventions

DRUG: dolutegravir
DRUG: lamivudine
DRUG: Continue current antiretroviral regimen

Sponsor

Babafemi Taiwo

Collaborators

[object Object]